CinDome Pharma, a CinRx portfolio company dedicated to advancing a safe, chronic therapy for gastroparesis, announced today that enrollment in the Phase 2 envisionGI trial of deudomperidone (CIN-102) ...

Please provide your email address to receive an email when new articles are posted on . Implementing quantitative sensory testing for patients with gastroparesis showed less sensation in idiopathic ...

Digestion is something most of us take for granted until it stops working correctly. Imagine eating a small meal and feeling painfully full for hours, or dealing with constant nausea because your ...

Nortriptyline is not more effective than a placebo in treating idiopathic gastroparesis, according to a multicenter, parallel-group, placebo-controlled, double-masked, randomized clinical trial ...

For individuals with suspected gastroparesis, a conditional recommendation was made against using 2-hour gastric emptying testing and in favor of 4-hour testing. HealthDay News — In a clinical ...

Gastroparesis affects thousands of people, often causing nausea, postprandial fullness, vomiting, discomfort, and major disruptions to quality of life. Bethesda, MD (Sept. 17, 2025) — The American ...

A recent study published by the Journal of the American Medical Association (JAMA) found that patients taking the drugs Ozempic (semaglutide) and Wegovy (liraglutide) for weight loss were more than ...

Please provide your email address to receive an email when new articles are posted on . Every August, gastrointestinal care providers and patient advocacy groups celebrate Gastroparesis Awareness ...

Until recently, Ozempic was a little-known diabetes medication. But, when mainstream media outlets and even medical schools began touting the drug’s weight loss benefits, Ozempic was quickly thrust ...

Digestive woes like gastroparesis and IBS, though distinct, cause similar discomfort. Gastroparesis slows stomach emptying, leading to nausea and early fullness. IBS impacts the intestines with cramps ...

Mohr Marketing targets high-value NAION & Gastroparesis claims, using 2026 medical data to secure medically-vetted, signed GLP-1 cases. ALLENTOWN, PA, UNITED STATES ...

ALLENTOWN, PA, UNITED STATES, February 23, 2026 /EINPresswire.com/ — As GLP-1 litigation enters a critical juncture, Mohr Marketing, LLC has announced the ...